Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid and small caps outperform
Mon, 10 Sep 11:30 am

Indian equity markets continued to trade in the green during the last two hours of trade. Sectoral indices represented a mixed performance with metal and healthcare stocks leading the list of gainers. FMCG and capital goods stocks witnessed selling pressure.

The BSE-Sensex is trading higher by 17 points and NSE-Nifty is trading flat. BSE Mid Cap and BSE Small Cap indices are currently up by 0.5% and 0.6% respectively. The rupee is trading at 55.37 to the US dollar.

IT stocks are trading in the green led by Moser-Baer India and Mahindra Satyam. According to a leading financial daily, Infosys is set to acquire Zurich based SAP implementation and management consultancy, Lodestone for about US$ 350 m. Lodestone has clients across manufacturing, automotive and life sciences segments. It has 850 employees including 750 consultants. Infosys acquisition will be in line with the Indian IT company's 3.0 strategy whereby it wants to expand its consulting and systems integration business. Post the deal, Infosys is expected to have around US$ 1 bn coming from its SAP practice.

Pharma stocks are trading strong led by Natco Pharma and Aurobindo Pharma. According to a leading financial daily, Cipla is planning to market the products on its own in major markets like USA. Till now the company has been operating primarily through sales and distribution partners in these markets. The company, which is forming a separate sales team for the US market, has started filing applications aggressively with the US Food and Drugs Administration (USFDA) seeking approval for its own generic products. This move is aimed at getting more value for products and technology. Cipla's strategy so far has been focused on manufacturing products while entering partnerships with various other companies for sales and distribution across markets. The current strategy has not allowed Cipla to grow as per its potential and that is probably a reason that it is now looking at a transformation.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid and small caps outperform". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.